Boehringer Ingelheim Corporation

Type: Company
Name: Boehringer Ingelheim Corporation
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Eli Lilly Gets Tentative FDA Approval For Diabetes Drug

Eli Lilly and Boehringer Ingelheim’s diabetes drug gains tentative FDA approval which is still subject to the decision about the patent lawsuit filed by SanofiPage 1 of 2Click Ticker to See live coverageEli Lilly and Co ( LLY ) announced on Monday, that ... [Published Bidness Etc - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

INSIDE INDIANA BUSINESS: Study suggests energy effort paying off

A report commissioned by the Indiana Utility Regulatory Commission suggests a statewide energy efficiency initiative's efforts have returned as much as $3 in benefits for each $1 spent from 2012-13. Energizing Indiana's programs are set to wrap up by ... [Published NWI Times - Aug 19 2014]
First reported Aug 18 2014 - Updated Aug 19 2014 - 1 reports

FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim's Basaglar(TM) (insulin glargine injection)

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire via COMTEX News Network/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar(TM) (insulin glargine injection), which is indicated to improve glycemic ... [Published PredictWallStreet - Aug 18 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD

RIDGEFIELD, Conn. , Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol ... [Published CBS Detroit - Aug 19 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Lilly Diabetes Drug Moves Forward

A diabetes treatment being developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Boehringer Ingelheim Corp. in Connecticut has received tentative approval from the U.S. Food and Drug Administration. Final approval for Basaglar is contingent ... [Published Inside INdiana Business - Aug 19 2014]
First reported Aug 14 2014 - Updated Aug 15 2014 - 1 reports

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

RIDGEFIELD, Conn. , Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted [10 yes, 3 no] that existing data supports ... [Published CBS Detroit - Aug 14 2014]
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Boehringer Ingelheim Corporation Goes On A Hiring Freeze And Plans To Chop Jobs

Boehringer Ingelheim is axing jobs but others are hiring too! Check it out! (Isn't it tempting?)Germany's Boehringer Ingelheim has implemented a hiring freeze and plans to reduce its headcount in its home market in a bid to reduce costs.The news was revealed ... [Published BioSpace - Aug 12 2014]
First reported Aug 11 2014 - Updated Aug 11 2014 - 1 reports

FDA approves ]ardiance® tablets for adults with type 2 diabetes

RIDGEFIELD, Conn., and INDIANAPOLIS— (BIPI) and have announced that the approved Jardiance· (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). Jardiance ... [Published Drug Discovery News - Aug 11 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

US FDA approves Jardiance tablets for adults with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company announced the US Food and Drug Administration (FDA) approved Jardiance (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose ... [Published PharmaBiz - Aug 05 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Medivir AB Licenses Respiratory Syncytial Virus Drug Program From Boehringer Ingelheim Corporation

HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir AB (STO:MVIR-B) today announces that it has entered a license agreement with Boehringer Ingelheim International GmbH for exclusive, global rights to a drug program for the treatment and prevention ... [Published BioSpace - Aug 04 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Boehringer Ingelheim: Benefits and Safety of Pradaxa Repeatedly Confirmed

– Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ) published today regarding Pradaxa® (dabigatran etexilate mesylate). We are concerned that this publication may alarm patients ... [Published Drugs.com - Jul 24 2014]
First reported Jun 30 2014 - Updated Jun 30 2014 - 1 reports

CHMP recommends Lilly/Boehringer's new insulin glargine product for approval in EU to treat type 1 and type 2 diabete

The Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine ... [Published PharmaBiz - Jun 30 2014]

Quotes

"The FDA's acceptance of our application for the fixed-dose combination of tiotropium and olodaterol is an important milestone for our company, and it reinforces Boehringer Ingelheim's steadfast commitment to COPD" said Sabine Luik, M D , senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc
"Because of the combined diabetes, development and commercialization experience of Lilly and Boehringer Ingelheim, we are confident that Basaglar, upon final approval, will become a valuable treatment choice for people who need a basal insulin to manage their type 1 or type 2 diabetes" said Christophe Arbet-Engels, M D , Ph D , vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals...
...RESPIMAT in the U S ," said Sabine Luik, M D , senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "At Boehringer Ingelheim, we have been committed to discovering and developing new treatments to help people affected by COPD for several decades. If approved, tiotropium RESPIMAT would build upon our heritage in treating respiratory diseases by equipping healthcare providers and their patients with an important new treatment option."
"Today's FDA approval of Jardiance provides an exciting new option in the treatment of adults with type 2 diabetes and demonstrates our commitment to these patients, as it marks the third diabetes medicine to emerge from our alliance pipeline" said Enrique Conterno, president, Lilly Diabetes

More Content

All (20) | News (20) | Reports (0) | Blogs (0) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
INSIDE INDIANA BUSINESS: Study suggests energy ... [Published NWI Times - Aug 19 2014]
Lilly Diabetes Drug Moves Forward [Published Inside INdiana Business - Aug 19 2014]
Boehringer Ingelheim Announces U.S. Filing for ... [Published CBS Detroit - Aug 19 2014]
Eli Lilly Gets Tentative FDA Approval For Diabe... [Published Bidness Etc - Aug 19 2014]
FDA Grants Tentative Approval for Lilly and Boe... [Published PredictWallStreet - Aug 18 2014]
Veterinary Health Markets [Published CW Atlanta - Aug 18 2014]
FDA Advisory Committee Recommends Approval of T... [Published CBS Detroit - Aug 14 2014]
Boehringer Ingelheim Corporation Goes On A Hiri... [Published BioSpace - Aug 12 2014]
FDA approves ]ardiance® tablets for adults with... [Published Drug Discovery News - Aug 11 2014]
US FDA approves Jardiance tablets for adults wi... [Published PharmaBiz - Aug 05 2014]
Medivir AB Licenses Respiratory Syncytial Virus... [Published BioSpace - Aug 04 2014]
Boehringer Ingelheim: Benefits and Safety of Pr... [Published Drugs.com - Jul 24 2014]
Benefits and Safety of Pradaxa® (dabigatran ete... [Published CEOWorld Magazine - Jul 23 2014]
CHMP recommends Lilly/Boehringer's new insulin ... [Published PharmaBiz - Jun 30 2014]
Boehringer Ingelheim, Lilly resubmit SGLT2 inhi... [Published PharmaBiz - Jun 19 2014]
Two phase III trials of empagliflozin/linaglipt... [Published PharmaBiz - Jun 17 2014]
EU grants marketing approval for Jardiance tabs... [Published PharmaBiz - May 24 2014]
US FDA accepts NDA filing of empagliflozin and ... [Published PharmaBiz - Apr 16 2014]
EU recommends approval of empagliflozin to redu... [Published PharmaBiz - Mar 24 2014]
CEO Cancer Gold Standard accreditation awarded ... [Published BioPortfolio - Dec 13 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.